Almirall and Ironwood Pharmaceuticals, Inc. IRWD announced today that the European Commission has granted marketing
authorization to Constella® (linaclotide 290mcg) for the
symptomatic treatment of moderate to severe Irritable Bowel Syndrome
with Constipation (IBS-C) in adults. This approval follows the positive
recommendation received from the European Committee for Medicinal
Products for Human Use (CHMP) in September.
Constella® is an oral, once-daily medication. Linaclotide,
the active ingredient in Constella®, is a guanylate cyclase-C
agonist (GCCA) with visceral analgesic and secretory activities, as
stated in the product label for European use. In non-clinical studies,
linaclotide has been shown to reduce visceral pain by decreasing
pain-fiber activity and to accelerate gastrointestinal transit
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in